DNLI
Price
$14.10
Change
-$0.39 (-2.69%)
Updated
Jun 27 closing price
Capitalization
2.05B
32 days until earnings call
LGND
Price
$114.15
Change
-$1.54 (-1.33%)
Updated
Jun 27 closing price
Capitalization
2.2B
43 days until earnings call
Interact to see
Advertisement

DNLI vs LGND

Header iconDNLI vs LGND Comparison
Open Charts DNLI vs LGNDBanner chart's image
Denali Therapeutics
Price$14.10
Change-$0.39 (-2.69%)
Volume$4.08M
Capitalization2.05B
Ligand Pharmaceuticals
Price$114.15
Change-$1.54 (-1.33%)
Volume$327.87K
Capitalization2.2B
DNLI vs LGND Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. LGND commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and LGND is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (DNLI: $14.10 vs. LGND: $114.15)
Brand notoriety: DNLI and LGND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 276% vs. LGND: 262%
Market capitalization -- DNLI: $2.05B vs. LGND: $2.2B
DNLI [@Biotechnology] is valued at $2.05B. LGND’s [@Biotechnology] market capitalization is $2.2B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileLGND’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • LGND’s FA Score: 0 green, 5 red.
According to our system of comparison, LGND is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 2 TA indicator(s) are bullish while LGND’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 2 bullish, 7 bearish.
  • LGND’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, LGND is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +1.51% price change this week, while LGND (@Biotechnology) price change was +0.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

LGND is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LGND($2.2B) has a higher market cap than DNLI($2.05B). LGND YTD gains are higher at: 6.533 vs. DNLI (-30.815). LGND has higher annual earnings (EBITDA): -122.1M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. LGND (209M). LGND has less debt than DNLI: LGND (4.45M) vs DNLI (48.6M). LGND has higher revenues than DNLI: LGND (181M) vs DNLI (0).
DNLILGNDDNLI / LGND
Capitalization2.05B2.2B93%
EBITDA-505.16M-122.1M414%
Gain YTD-30.8156.533-472%
P/E RatioN/A46.19-
Revenue0181M-
Total Cash818M209M391%
Total Debt48.6M4.45M1,093%
FUNDAMENTALS RATINGS
DNLI vs LGND: Fundamental Ratings
DNLI
LGND
OUTLOOK RATING
1..100
6318
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
10058
SMR RATING
1..100
9493
PRICE GROWTH RATING
1..100
6344
P/E GROWTH RATING
1..100
9992
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LGND's Valuation (76) in the Biotechnology industry is in the same range as DNLI (93). This means that LGND’s stock grew similarly to DNLI’s over the last 12 months.

LGND's Profit vs Risk Rating (58) in the Biotechnology industry is somewhat better than the same rating for DNLI (100). This means that LGND’s stock grew somewhat faster than DNLI’s over the last 12 months.

LGND's SMR Rating (93) in the Biotechnology industry is in the same range as DNLI (94). This means that LGND’s stock grew similarly to DNLI’s over the last 12 months.

LGND's Price Growth Rating (44) in the Biotechnology industry is in the same range as DNLI (63). This means that LGND’s stock grew similarly to DNLI’s over the last 12 months.

LGND's P/E Growth Rating (92) in the Biotechnology industry is in the same range as DNLI (99). This means that LGND’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLILGND
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
74%
Momentum
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
72%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 19 days ago
73%
Declines
ODDS (%)
Bearish Trend 10 days ago
80%
Bearish Trend 3 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
81%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCIKX17.420.21
+1.22%
NYLI PineStone International Eq Inv Cl
CIUEX13.030.13
+1.01%
Six Circles International Uncon Eq
MMIAX8.420.08
+0.96%
MassMutual International Eq A
TSNRX20.710.17
+0.83%
Touchstone Sands Capital Select Gr R6
RYOTX10.980.01
+0.09%
Royce Micro-Cap Invmt

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-2.69%
BEAM - DNLI
61%
Loosely correlated
-1.98%
NRIX - DNLI
59%
Loosely correlated
+0.17%
RGNX - DNLI
58%
Loosely correlated
-4.11%
ARWR - DNLI
57%
Loosely correlated
+0.06%
ATXS - DNLI
57%
Loosely correlated
N/A
More

LGND and

Correlation & Price change

A.I.dvisor indicates that over the last year, LGND has been loosely correlated with ACLX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LGND jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LGND
1D Price
Change %
LGND100%
-1.33%
ACLX - LGND
48%
Loosely correlated
+0.90%
CRNX - LGND
47%
Loosely correlated
-0.10%
ROIV - LGND
47%
Loosely correlated
-1.81%
CRSP - LGND
47%
Loosely correlated
N/A
DNLI - LGND
46%
Loosely correlated
-2.69%
More